Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from RELIEF THERAPEUTICS Holding ( (CH:RLF) ) is now available.
Relief Therapeutics has received the FDA’s Rare Pediatric Disease designation for its product RLF-TD011, aimed at treating epidermolysis bullosa (EB), a rare genetic skin disorder. This designation highlights the potential of RLF-TD011 to advance EB wound care by offering a novel treatment option that modulates the wound microbiome and reduces pathogenic colonization. The designation may also allow Relief to receive a Priority Review Voucher, which could expedite FDA review for future marketing applications, potentially enhancing the company’s market position and offering significant benefits to stakeholders.
More about RELIEF THERAPEUTICS Holding
Relief Therapeutics Holding SA is a commercial-stage biopharmaceutical company based in Geneva, Switzerland. The company specializes in developing innovative treatments for rare and debilitating diseases, with a focus on drug delivery systems and drug repurposing. Relief’s clinical pipeline targets unmet medical needs in rare dermatological, metabolic, and respiratory conditions. The company is listed on the SIX Swiss Exchange and quoted in the U.S. on OTCQB.
Average Trading Volume: 23,719
Current Market Cap: CHF26.66M
For an in-depth examination of RLF stock, go to TipRanks’ Stock Analysis page.